All In Biotech

Drug Trial Radar · NCT06914869

Drug-Drug Interaction Potential of Mavorixafor

A Phase I, Randomized, Open-label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of a Moderate and a Strong CYP3A Inducer on the Pharmacokinetics and Safety of Mavorixafor in Healthy Male and Female Participants

Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Feb 18, 2025

Primary completion

May 19, 2025

Study completion May 19, 2025

Sponsor

Lead sponsor
X4 PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.

Conditions

  • Healthy Participants

Interventions

  • MavorixaforDrug

    Mavorixafor will be administered per schedule specified in the arm description.

  • CarbamazepineDrug

    Carbamazepine will be administered per schedule specified in the arm description.

  • EfavirenzDrug

    Efavirenz will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With CarbamazepineTime frame: Predose up to 120 hours postdose on Days 1 and 18
  2. Cohort 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With CarbamazepineTime frame: Predose up to 120 hours postdose on Days 1 and 18
  3. Cohort 2: Cmax of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With EfavirenzTime frame: Predose up to 120 hours postdose on Days 1 and 18
  4. Cohort 2: AUC0-last of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With EfavirenzTime frame: Predose up to 120 hours postdose on Days 1 and 18

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel International LLC

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.